Blocking NKG2A with Monalizumab (a humanized anti-NKG2A mAb) enhances tumor immunity in combination with ICI against PD-L1 by promoting NK cell and CTL cell effector functions in mice and humans and enhances ADCC in combination with Cetuximab against a head and neck carcinoma cell line, indicating that its mechanism of action directly impacts on NK cell effector functions (192–194). The gene discussed is CD274; the disease is neoplasm.